Funding to Optimize and Expand the Company’s Current Clinical Surveillance Solutions, Continue R&D and Enhance Customer Service
CHARLOTTE, N.C. – January 9, 2017 – PeraHealth, a provider of predictive, real-time clinical surveillance solutions, announces it closed $14 million in financing from Mainsail Partners, a growth equity firm. The funding will be used to build on the company’s existing clinical surveillance solutions for hospital and health systems. The capital will also be used to grow PeraHealth’s internal team in the areas of customer service and clinical adoption, as well as to support ongoing research and development.
“We’re very impressed with PeraHealth’s products, which have been referenced in more than 20 peer-reviewed publications, including recent sepsis research in the Journal of Critical Care,” said Michael Anderson, a partner at Mainsail Partners. “Customers have demonstrated meaningful clinical improvements – like reductions in mortality rates – by using PeraHealth. Also impressive is the ease by which customers integrate the product into their daily routine and Electronic Medical Record software. We’re excited to support the management team, which has decades of experience serving hospitals.”
As healthcare continues its progression to value-based care, the industry is still riddled with high costs surrounding chronic diseases and infections. For example, sepsis kills 258,000 people in the U.S. every year and costs the U.S. healthcare system nearly $24 billion annually, according to the Sepsis Alliance. PeraHealth is lowering the costs associated with the most expensive illnesses, such as sepsis, by helping clinicians identify patients most in need of care sooner, for earlier intervention through the use of its digital health solutions and Rothman Index, a proprietary patient acuity model and scoring system. This funding will help grow the company’s existing product offerings, with the addition of PeraWatch, a telehealth and remote monitoring solution, and PeraMobile, an app which tracks and identifies at-risk patients for clinicians on the go.
“We’ve made significant strides in helping improve outcomes and lower costs with our current customers, but we’ve only scratched the surface and know we can broaden our solutions to help more health systems save patients’ lives,” says Stephanie Alexander, CEO of PeraHealth. “This funding provides PeraHealth with the resources to continue to transform healthcare through the intelligent use of data and grow our product portfolio built on the success of the Rothman Index.”
PeraHealth solutions are in use by more than 80 leading hospitals and care providers and help determine when to discharge patients; prioritize patient bedside visits and nursing assignments; improve documentation accuracy and timeliness; optimize ICU bed use; and identify opportunities for palliative care consults. Customers include Yale New Haven Health System, Houston Methodist, Children’s Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and Mission Health. PeraHealth products are integrated with all major EHR vendors, enabling care providers to monitor patients at the unit, hospital and system-level.
About Mainsail Partners
Mainsail Partners is a growth equity firm that invests exclusively in growing bootstrapped companies, primarily in three core industry sectors: healthcare, software and technology-enabled services. The San Francisco-based firm has a team of experienced operating professionals to help entrepreneurs scale their businesses and accelerate growth. Recent investments include 3PL Central, Brilliant Earth, Ncontracts, nCourt, Netchemia, Nexus Systems, PlayMaker CRM, SentryOne and Zen Planner. The firm has raised over $750 million in committed capital. For further information, please visit www.mainsailpartners.com.